ABSTRACT
BACKGROUND: Mononcyclic ß-lactams are regarded as the most resistant class of ß-lactams against a series of ß-lactamases, although they possess limited antibacterial activity. Aztreonam, being the first clinically approved monobactam, needs broad-spectrum efficacy through structural modification. OBJECTIVE: We strive to synthesize a number of monocyclic ß-lactams by varying the substituents at N1, C3, and C4 positions of azetidinone ring and study the antimicrobial effect on variable bacterial strains. METHODS: Seven new monobactam derivatives 23a-g, containing substituted-amidine moieties linked to the azetidinone ring via thiazole linker, were synthesized through multistep synthesis. The final compounds were investigated for their in vitro antibacterial activities using the broth microdilution method against ten bacterial strains of clinical interest. The minimum inhibitory concentrations (MICs) of newly synthesized derivatives were compared with aztreonam, ceftazidime, and meropenem, existing clinical antibiotics. RESULTS: All compounds 23a-g showed higher antibacterial activities (MIC 0.25 µg/mL to 64 µg/mL) against tested strains as compared to aztreonam (MIC 16 µg/mL to >64 µg/mL) and ceftazidime (MIC >64 µg/mL). However, all compounds, except 23d, exhibited lower antibacterial activity against all tested bacterial strains compared to meropenem. CONCLUSION: Compound 23d showed comparable or improved antibacterial activity (MIC 0.25 µg/mL to 2 µg/mL) to meropenem (MIC 1 µg/mL to 2 µg/mL) in the case of seven bacterial species. Therefore, compound 23d may be a valuable lead target for further investigations against multi-drug resistant Gram-negative bacteria.
Subject(s)
Anti-Bacterial Agents , Monobactams , Amidines , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Microbial Sensitivity Tests , Monobactams/chemistry , Monobactams/pharmacology , beta-Lactamases , beta-Lactams/pharmacologyABSTRACT
Novel antimicrobial strategies are urgently required because of the rising threat of multi drug resistant bacterial strains and the infections caused by them. Among the available target structures, the so-called penicillin binding proteins are of particular interest, owing to their good accessibility in the periplasmic space, and the lack of homologous proteins in humans, reducing the risk of side effects of potential drugs. In this report, we focus on the interaction of the innovative ß-lactam antibiotic AIC499 with penicillin binding protein 3 (PBP3) from Escherichia coli and Pseudomonas aeruginosa. This recently developed monobactam displays broad antimicrobial activity, against Gram-negative strains, and improved resistance to most classes of ß-lactamases. By analyzing crystal structures of the respective complexes, we were able to explore the binding mode of AIC499 to its target proteins. In addition, the apo structures determined for PBP3, from P. aeruginosa and the catalytic transpeptidase domain of the E. coli orthologue, provide new insights into the dynamics of these proteins and the impact of drug binding.
Subject(s)
Monobactams/metabolism , Penicillin-Binding Proteins/chemistry , Penicillin-Binding Proteins/metabolism , Crystallography, X-Ray , Escherichia coli Proteins/chemistry , Escherichia coli Proteins/metabolism , Magnetic Resonance Spectroscopy , Models, Molecular , Monobactams/chemistry , Penicillin-Binding Proteins/genetics , Protein Conformation , Pseudomonas aeruginosaABSTRACT
Monobactams play an important role in antibiotic drug discovery. Based on the structural characteristics of aztreonam and its biological targets, six new monobactam derivatives (2a-c and 3a-c) were synthesized and their in vitro antibacterial activities were investigated. Compounds 2a-c showed higher activities against tested gram-negative bacteria than that of parent aztreonam. Monobactam 2c exhibited the most potent activities, with MIC ranging from 0.25 to 2 µg/mL against most bacteria.
Subject(s)
Anti-Bacterial Agents/pharmacology , Gram-Negative Bacteria/drug effects , Monobactams/pharmacology , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Dose-Response Relationship, Drug , Microbial Sensitivity Tests , Molecular Structure , Monobactams/chemical synthesis , Monobactams/chemistry , Structure-Activity RelationshipABSTRACT
A monocyclic ring in their structure characterizes monobactams, a subclass of ß-lactam antibiotics. Many of these compounds have a bactericidal mechanism of action and acts as penicillin and cephalosporins, interfering with bacterial cell wall biosynthesis. The synthesis of novel ß-lactams is an emerging area of organic synthesis research due to the problem of increasing bacterial resistance to existing ß -lactam antibiotics, and, in this way, new compounds have been presented with several structural modifications, aiming to improve biological activities. Among the biological activities studied, the most outstanding are antibacterial, antitubercular, anticholesterolemic, anticancer, antiinflammatory, antiviral, and anti-enzymatic, among others. This review explores the vast number of works related to monocyclic ß-lactams, compounds of great importance in scientific research.
Subject(s)
Anti-Infective Agents/pharmacology , Anti-Inflammatory Agents/pharmacology , Antineoplastic Agents/pharmacology , Antitubercular Agents/pharmacology , Monobactams/pharmacology , Anti-Infective Agents/chemical synthesis , Anti-Infective Agents/chemistry , Anti-Inflammatory Agents/chemical synthesis , Anti-Inflammatory Agents/chemistry , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Antitubercular Agents/chemical synthesis , Antitubercular Agents/chemistry , Molecular Structure , Monobactams/chemical synthesis , Monobactams/chemistryABSTRACT
Based on the structural characteristics of aztreonam (AZN) and its target PBP3, a series of new monobactam derivatives bearing various substituents on oxime residue were prepared and evaluated for their antibacterial activities against susceptible and resistant Gram-negative bacteria. Among them, compounds 8p and 8r displayed moderate potency with MIC values of 0.125-32 µg/mL against most tested Gram-negative strains, comparable to AZN. Meanwhile, the combination of 8p and 8r with avibactam as a ß-lactamases inhibitor, in a ratio of 1:16, showed a promising synergistic effect against both ESBLs- and NDM-1-producing K. pneumoniae, with significantly reduced MIC values up to 8-fold and >256-fold respectively. Furthermore, both of them demonstrated excellent safety profiles both in vitro and in vivo. The results provided powerful information for further structural optimization of monobactam antibiotics to fight ß-lactamase-producing resistant Gram-negative bacteria.
Subject(s)
Anti-Bacterial Agents/pharmacology , Escherichia coli/drug effects , Klebsiella pneumoniae/drug effects , Monobactams/pharmacology , Oximes/pharmacology , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/chemistry , Dose-Response Relationship, Drug , Microbial Sensitivity Tests , Molecular Structure , Monobactams/chemical synthesis , Monobactams/chemistry , Oximes/chemistry , Structure-Activity RelationshipABSTRACT
Monobactam antibiotic 1 is active against Gram-negative bacteria even though it has a higher molecular weight (MW) than the limit of 600 Da typically applied in designing such compounds. On the basis of 2D NMR data, the compound is able to adopt a compact conformation. The dimensions, projection area, and dipole moment derived from this conformation are compatible with porin permeation, as are locations of polar groups upon superimposition to the crystal structure of ampicillin bound to E. coli OmpF porin. Minimum inhibitory concentration (MIC) shifts in a porin knock-out strain are also consistent with 1 predominately permeating through porins. In conclusion, we describe a carefully characterized case of a molecule outside default design parameters where MW does not adequately represent the 3D shape more directly related to permeability. Leveraging 3D design criteria would open up additional chemical space currently underutilized due to limitations perceived in 2D.
Subject(s)
Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Gram-Negative Bacteria/drug effects , Monobactams/chemistry , Monobactams/pharmacology , Escherichia coli/drug effects , Escherichia coli Proteins/drug effects , Hydrophobic and Hydrophilic Interactions , Microbial Sensitivity Tests , Models, Molecular , Molecular Conformation , Molecular Weight , Permeability , PorinsABSTRACT
Nuclear magnetic resonance and infrared spectroscopy have been used to investigate the formation of complexes of BAL30072 with Fe3+ and Ga3+ in solution and to collect geometrical parameters supporting reliable 3D structure models. Structural models for the ligand-metal complexes with different stoichiometries have been characterized using density functional theory calculations. Blind ensemble docking to the PiuA receptor from P. aeruginosa was performed for the different complexes to compare binding affinities and statistics of the residues most frequently contacted. When compared to analogues, BAL30072 was found to have an intrinsic propensity to form complexes with low ligand-to-metal stoichiometry. By using one of the sulfate oxygen atoms as a third donor in addition to the bidentate pyridinone moiety, BAL30072 can form a L2M complex, which was predicted to be the one with the best binding affinity to PiuA. The example of BAL30072 strongly suggests that a lower stoichiometry might be the one recognized by the receptor, so that to focus only on the highest stoichiometry might be misleading for siderophores with less than six donors.
Subject(s)
Anti-Bacterial Agents/pharmacology , Bacterial Outer Membrane Proteins/antagonists & inhibitors , Monobactams/pharmacology , Pseudomonas aeruginosa/drug effects , Siderophores/chemistry , Thiazoles/pharmacology , Anti-Bacterial Agents/chemistry , Bacterial Outer Membrane Proteins/chemistry , Microbial Sensitivity Tests , Molecular Conformation , Molecular Docking Simulation , Monobactams/chemistry , Thiazoles/chemistryABSTRACT
A series of novel pyridone conjugated monobactams with various substituents at the (4) position were synthesized and evaluated for their antibacterial activities against a panel of multidrug-resistant (MDR) Gram-negative bacteria in vitro. Compounds 46d, 54 and 75e displayed good to moderate activities against P. aeruginosa, among which the activity of 75e against P. aeruginosa was comparable to that of BAL30072 under iron limitation condition. Compounds 35, 46d, 54, 56a, 56c and 56d exhibited good to excellent antibacterial activities against E. coli and K. pneumoniae, which were comparable or superior to that of BAL30072. In vitro liver microsomal stability was further evaluated and the results manifested that Compounds 35, 46d and 54 were metabolically stable in human liver microsomes.
Subject(s)
Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Gram-Negative Bacteria/drug effects , Monobactams/chemistry , Monobactams/pharmacology , Anti-Bacterial Agents/chemical synthesis , Drug Design , Drug Resistance, Multiple , Drug Resistance, Multiple, Bacterial , Escherichia coli/drug effects , Gram-Negative Bacterial Infections/drug therapy , Humans , Klebsiella pneumoniae/drug effects , Microbial Sensitivity Tests , Monobactams/chemical synthesis , Pseudomonas aeruginosa/drug effects , Pyridones/chemical synthesis , Pyridones/chemistry , Pyridones/pharmacologyABSTRACT
Metallo-ß-lactamases (MBLs), such as New Delhi metallo-ß-lactamase (NDM-1) have spread world-wide and present a serious threat. Expression of MBLs confers resistance in Gram-negative bacteria to all classes of ß-lactam antibiotics, with the exception of monobactams, which are intrinsically stable to MBLs. However, existing first generation monobactam drugs like aztreonam have limited clinical utility against MBL-expressing strains because they are impacted by serine ß-lactamases (SBLs), which are often co-expressed in clinical isolates. Here, we optimized novel monobactams for stability against SBLs, which led to the identification of LYS228 (compound 31). LYS228 is potent in the presence of all classes of ß-lactamases and shows potent activity against carbapenem-resistant isolates of Enterobacteriaceae (CRE).
Subject(s)
Anti-Bacterial Agents/pharmacology , Bacterial Proteins/metabolism , Carbapenem-Resistant Enterobacteriaceae/drug effects , Monobactams/pharmacology , beta-Lactam Resistance/drug effects , beta-Lactamases/metabolism , Animals , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/metabolism , Aztreonam/pharmacology , CHO Cells , Cricetulus , Drug Stability , Escherichia coli/drug effects , Female , Humans , Meropenem , Mice , Microbial Sensitivity Tests , Molecular Structure , Monobactams/adverse effects , Monobactams/chemistry , Monobactams/metabolism , Pseudomonas aeruginosa/drug effects , Receptors, GABA-A/metabolism , Seizures/chemically induced , Structure-Activity Relationship , Thienamycins/pharmacologyABSTRACT
Due to the widespread emergence of resistant bacterial strains, an urgent need for the development of new antibacterial agents with novel modes of action has emerged. The discovery of naturally occurring monocyclic ß-lactams in the late 1970s, mainly active against aerobic Gram-negative bacteria, has introduced a new approach in the design and development of novel antibacterial ß-lactam agents. The main goal was the derivatization of the azetidin-2-one core in order to improve their antibacterial potency, broaden their spectrum of activity, and enhance their ß-lactamase stability. In that respect, our review covers the updates in the field of monocyclic ß-lactam antibiotics during the last three decades, taking into account an extensive collection of references. An overview of the relationships between the structural features of these monocyclic ß-lactams, classified according to their N-substituent, and the associated antibacterial or ß-lactamase inhibitory activities is provided. The different paragraphs disclose a number of well-established classes of compounds, such as monobactams, monosulfactams, monocarbams, monophosphams, nocardicins, as well as other known representative classes. Moreover, this review draws attention to some less common but, nevertheless, possibly important types of monocyclic ß-lactams and concludes by highlighting the recent developments on siderophore-conjugated classes of monocyclic ß-lactams.
Subject(s)
Anti-Bacterial Agents/pharmacology , Monobactams/pharmacology , beta-Lactamase Inhibitors/pharmacology , beta-Lactamases/metabolism , Anti-Bacterial Agents/chemistry , Monobactams/chemistry , Siderophores/chemistry , Structure-Activity Relationship , beta-Lactamase Inhibitors/chemistryABSTRACT
The N-sulfonated monocyclic ß-lactam ring characteristic of the monobactams confers resistance to zinc metallo-ß-lactamases and affords the most effective class to combat carbapenem-resistant enterobacteria (CRE). Here we report unprecedented nonribosomal peptide synthetase activities, wherein an assembled tripeptide is N-sulfonated in trans before direct synthesis of the ß-lactam ring in a noncanonical, cysteine-containing thioesterase domain. This means of azetidinone synthesis is distinct from the three others known in nature.
Subject(s)
Anti-Bacterial Agents/biosynthesis , Carbapenem-Resistant Enterobacteriaceae/drug effects , Monobactams/biosynthesis , Peptide Biosynthesis, Nucleic Acid-Independent , Peptide Synthases/metabolism , Pseudomonas/metabolism , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Catalytic Domain , Drug Resistance, Multiple, Bacterial/drug effects , Monobactams/chemistry , Monobactams/pharmacology , Peptide Biosynthesis, Nucleic Acid-Independent/genetics , Peptide Synthases/genetics , StereoisomerismABSTRACT
Bromine induced lactamization of vinyl acetohydroxamates facilitated syntheses of monocyclic ß-lactams suitable for incorporation of a thiomethyl and extended functionality at the C(4) position. Elaboration of the resulting substituted N-hydroxy-2-azetidinones allowed incorporation of functionalized α-amino substituents appropriate for enhancement of antibiotic activity. Evaluation of antibacterial activity against a panel of Gram-positive and Gram-negative bacteria revealed structure-activity relationships (SAR) and identification of potent new monobactam antibiotics. The corresponding bis-catechol conjugate, 42, has excellent activity against Gram-negative bacteria including carbapenemase and carbacephalosporinase producing strains of Acinetobacter baumannii, which have been listed by the WHO as being of critical concern worldwide.
Subject(s)
Gram-Negative Bacteria/drug effects , Monobactams/chemistry , beta-Lactams/chemistry , Acinetobacter baumannii/drug effects , Acinetobacter baumannii/enzymology , Bacterial Proteins , Catechols/pharmacology , Methods , Microbial Sensitivity Tests , Monobactams/chemical synthesis , Structure-Activity Relationship , beta-LactamasesABSTRACT
The development of biomaterials able to act against a wide range of bacteria, including antibiotic resistant bacteria, is of great importance since bacterial colonization is one of the main causes of implant failure. In this work, we explored the possibility to functionalize hydroxyapatite (HA) nanocrystals with some monocyclic N-thio-substituted ß-lactams. To this aim, a series of non-polar azetidinones have been synthesized and characterized. The amount of azetidinones loaded on HA could be properly controlled on changing the polarity of the loading solution and it can reach values up to 17 wt%. Data on cumulative release in aqueous solution show different trends which can be related to the lipophilicity of the molecules and can be modulated by suitable groups on the azetidinone. The examined ß-lactams-HA composites display good antibacterial activity against reference Gram-positive and Gram-negative bacteria. However, the results of citotoxicity and antibacterial tests indicate that HA loaded with 4-acetoxy-1-(methylthio)-azetidin-2-one displays the best performance. In fact, this material strongly inhibited the bacterial growth of both methicillin resistant and methicillin susceptible clinical isolates of S. aureus from surgical bone biopsies, showing to be a very good candidate as a new functional biomaterial with enhanced antibacterial activity.
Subject(s)
Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Biocompatible Materials/chemistry , Durapatite/chemistry , Monobactams/chemistry , Monobactams/pharmacology , Anti-Bacterial Agents/chemical synthesis , Azetidines/chemistry , Azetidines/pharmacology , Bacteria/drug effects , Drug Carriers , Drug Liberation , Humans , Microbial Sensitivity Tests , Molecular Structure , Monobactams/chemical synthesis , Spectroscopy, Fourier Transform InfraredABSTRACT
Conjugating a siderophore to an antibiotic is a promising strategy to overcome the permeability-mediated resistance of Gram-negative pathogens. On the basis of the structure of BAL30072, novel pyridone-conjugated monosulfactams incorporating diverse substituents into the methylene linker between the 1,3-dihydroxypyridin-4(1H)-one and the aminothiazole oxime were designed and synthesized. Structure-activity relationship studies revealed that a variety of substituents were tolerated, with isopropyl (compound 12c) and methylthiomethyl (compound 16a) showing the best efficacy against multidrug-resistant (MDR) Gram-negative pathogens. In addition, compound 12c exhibits a good free fraction rate in an in vitro human plasma protein binding test, along with a low clearance and favorable plasma exposure in vivo. In a murine systemic infection model with MDR Klebsiella pneumoniae, compound 12c shows an ED50 of 10.20 mg/kg. Taken together, the results indicate that compound 12c is a promising drug candidate for the treatment of serious infections caused by MDR Gram-negative pathogens.
Subject(s)
Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Drug Resistance, Multiple, Bacterial , Gram-Negative Bacteria/drug effects , Gram-Negative Bacterial Infections/drug therapy , Monobactams/chemistry , Monobactams/pharmacology , Thiazoles/chemistry , Thiazoles/pharmacology , Animals , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/therapeutic use , Drug Discovery , Escherichia coli/drug effects , Escherichia coli Infections/drug therapy , Humans , Klebsiella Infections/drug therapy , Klebsiella pneumoniae/drug effects , Male , Mice , Microbial Sensitivity Tests , Monobactams/blood , Monobactams/therapeutic use , Pyridones/blood , Pyridones/chemistry , Pyridones/pharmacology , Pyridones/therapeutic use , Rats, Sprague-Dawley , Structure-Activity Relationship , Thiazoles/blood , Thiazoles/therapeutic useABSTRACT
In this issue of Cell Chemical Biology, Li et al. (2017) report on the biosynthesis of the monobactam sulfazecin by Pseudomonas acidophila and hypothesize a novel mechanism of ß-lactam ring formation. As monobactam antibiotics are unaffected by some emerging resistance mechanisms (particularly metallo-ß-lactamases), this discovery opens prospects to engineer ß-lactam antibiotics against multi-drug resistant pathogens.
Subject(s)
Drug Resistance, Multiple, Bacterial/drug effects , Monobactams/pharmacology , Pseudomonas/metabolism , Molecular Structure , Monobactams/biosynthesis , Monobactams/chemistry , beta-Lactams/metabolismABSTRACT
The monobactams, exemplified by the natural product sulfazecin, are the only class of ß-lactam antibiotics not inactivated by metallo-ß-lactamases, which confer bacteria with extended-spectrum ß-lactam resistance. We screened a transposon mutagenesis library from Pseudomonas acidophila ATCC 31363 and isolated a sulfazecin-deficient mutant that revealed a gene cluster encoding two non-ribosomal peptide synthetases (NRPSs), a methyltransferase, a sulfotransferase, and a dioxygenase. Three modules and an aberrant C-terminal thioesterase (TE) domain are distributed across the two NRPSs. Biochemical examination of the adenylation (A) domains provided evidence that L-2,3-diaminopropionate, not L-serine as previously thought, is the direct source of the ß-lactam ring of sulfazecin. ATP/PPi exchange assay also revealed an unusual substrate selectivity shift of one A domain when expressed with or without the immediately upstream condensation domain. Gene inactivation analysis defined a cluster of 13 open reading frames sufficient for sulfazecin production, precursor synthesis, self-resistance, and regulation. The identification of a key intermediate supported a proposed NRPS-mediated mechanism of sulfazecin biosynthesis and ß-lactam ring formation distinct from the nocardicins, another NRPS-derived subclass of monocyclic ß-lactam. These findings will serve as the basis for further biosynthetic research and potential engineering of these important antibiotics.
Subject(s)
Monobactams/biosynthesis , Multigene Family/genetics , Pseudomonas/metabolism , Drug Resistance, Multiple, Bacterial/drug effects , Molecular Conformation , Monobactams/chemistry , Monobactams/pharmacology , Peptide Synthases/genetics , Peptide Synthases/metabolism , Pseudomonas/genetics , beta-Lactams/metabolismABSTRACT
The monobactam antibiotic aztreonam is used to treat cystic fibrosis patients with chronic pulmonary infections colonized by Pseudomonas aeruginosa strains expressing CTX-M extended-spectrum ß-lactamases. The protonation states of active-site residues that are responsible for hydrolysis have been determined previously for the apo form of a CTX-M ß-lactamase but not for a monobactam acyl-enzyme intermediate. Here we used neutron and high-resolution X-ray crystallography to probe the mechanism by which CTX-M extended-spectrum ß-lactamases hydrolyze monobactam antibiotics. In these first reported structures of a class A ß-lactamase in an acyl-enzyme complex with aztreonam, we directly observed most of the hydrogen atoms (as deuterium) within the active site. Although Lys 234 is fully protonated in the acyl intermediate, we found that Lys 73 is neutral. These findings are consistent with Lys 73 being able to serve as a general base during the acylation part of the catalytic mechanism, as previously proposed.
Subject(s)
Anti-Bacterial Agents/pharmacology , Aztreonam/pharmacology , Monobactams/pharmacology , beta-Lactamases/metabolism , Anti-Bacterial Agents/chemistry , Aztreonam/chemistry , Catalytic Domain , Crystallography, X-Ray , Microbial Sensitivity Tests , Monobactams/chemistry , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/enzymology , beta-Lactamases/geneticsABSTRACT
A series of monobactam derivatives were prepared and evaluated for their antibacterial activities against susceptible and resistant Gram-negative strains, taking Aztreonam and BAL30072 as the leads. Six conjugates (12a-f) bearing PIH-like siderophore moieties were created to enhance the bactericidal activities against Gram-negative bacteria based on Trojan Horse strategy, and all of them displayed potencies against susceptible Gram-negative strains with MIC ≤ 8 µg/mL. SAR revealed that the polar substituents on the oxime side chain were beneficial for activities against resistant Gram-negative bacteria. Compounds 19c and 33a-b exhibited the promising potencies against ESBLs-producing E. coli and Klebsiella pneumoniae with MICs ranging from 2 µg/mL to 8 µg/mL. These results offered powerful information for further strategic optimization in search of the antibacterial candidates against MDR Gram-negative bacteria.
Subject(s)
Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Gram-Negative Bacteria/drug effects , Gram-Negative Bacterial Infections/drug therapy , Monobactams/chemistry , Monobactams/pharmacology , Anti-Bacterial Agents/chemical synthesis , Aztreonam/analogs & derivatives , Aztreonam/chemical synthesis , Aztreonam/pharmacology , Drug Design , Escherichia coli/drug effects , Humans , Klebsiella pneumoniae/drug effects , Microbial Sensitivity Tests , Models, Molecular , Monobactams/chemical synthesis , Structure-Activity Relationship , Thiazoles/chemical synthesis , Thiazoles/chemistry , Thiazoles/pharmacologyABSTRACT
To identify new agents for the treatment of multi-drug-resistant Pseudomonas aeruginosa, we focused on siderophore-conjugated monocarbams. This class of monocyclic ß-lactams are stable to metallo-ß-lactamases and have excellent P. aeruginosa activities due to their ability to exploit the iron uptake machinery of Gram-negative bacteria. Our medicinal chemistry plan focused on identifying a molecule with optimal potency and physical properties and activity for in vivo efficacy. Modifications to the monocarbam linker, siderophore, and oxime portion of the molecules were examined. Through these efforts, a series of pyrrolidinone-based monocarbams with good P. aeruginosa cellular activity (P. aeruginosa MIC90 = 2 µg/mL), free fraction levels (>20% free), and hydrolytic stability (t1/2 ≥ 100 h) were identified. To differentiate the lead compounds and enable prioritization for in vivo studies, we applied a semi-mechanistic pharmacokinetic/pharmacodynamic model to enable prediction of in vivo efficacy from in vitro data.
Subject(s)
Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/pharmacokinetics , Drug Discovery , Monobactams/pharmacology , Monobactams/pharmacokinetics , Pseudomonas Infections/drug therapy , Pseudomonas aeruginosa/drug effects , Siderophores/metabolism , Animals , Humans , Male , Monobactams/chemistry , Pseudomonas Infections/microbiology , Rats , Rats, Wistar , Structure-Activity Relationship , beta-Lactamases/chemistryABSTRACT
An efficient method to synthesize the ß-lactams with high regioselectivity via Pd-catalyzed C(sp(3))-H bond activation and intramolecular amination of simple and readily available aminoquinoline carboxamides was demonstrated. C6F5I plays a significant role in the formation of the C-N bond of the four-membered ring ß-lactams. High yield along with wide substrate scope and functional group tolerance makes this reaction applicable to build natural-product-derived ß-lactams. This method has been applied to the efficient synthesis of the ß-lactamase inhibitor MK-8712.